RecruitingPhase 2NCT06665100

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

Efficacy and Safety of PUL-042 Inhalation Solution in Reducing Lower Respiratory Tract Complications in Patients With Hematologic Malignancies and Recipients of Hematopoietic Stem Cell Transplantation (HSCT) With Documented Viral Infections With PIV, hMPV or RSV

Sponsor

Pulmotect, Inc.

Enrollment

100 participants

Start Date

Jun 27, 2025

Study Type

INTERVENTIONAL

Conditions

Hematologic Malignancies Hematopoietic Stem Cell Transplant (HSCT)

Summary

The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation with documented viral infections due to PIV, hMPV, or RSV. PUL-042 or a placebo will be administered 3 times over a 6-day period. The total duration of the study will be approximately 30 days.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called PUL-042 and a drug called Placebo for people with hematologic malignancies and hematopoietic stem cell transplant (hsct). The study is currently recruiting participants at 11 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPUL-042

Pam2 : ODN (PUL-042) PUL-042 Inhalation Solution

DRUGPlacebo

Sterile Saline for Inhalation

Locations(11)

City of Hope National Medical Center

Duarte, California, United States

Northside Hospital

Atlanta, Georgia, United States

Johns Hopkins Hospital

Baltimore, Maryland, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, United States

University of Minnesota

Minneapolis, Minnesota, United States

John Theurer Cancer Center

Hackensack, New Jersey, United States

Lineberger Cancer

Chapel Hill, North Carolina, United States

OU Health Physicians - Infectious Disease Clinic

Oklahoma City, Oklahoma, United States

University of Texas MD Anderson MD Anderson Cancer Center

Houston, Texas, United States

Fred Hutchinson Cancer Center

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06665100

Related Trials

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

NCT04728893120 locations

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

NCT0682316722 locations

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

NCT057241211 location

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873780 locations

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

NCT0458892226 locations